Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063713 · ClinicalTrials.gov registry record · Phase 2
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 study of Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT00063713 is a Phase 2 study of Mantle Cell Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 152 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT00063713, a Phase 2 study of Mantle Cell Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
Conditions Studied
Interventions
- DRUG VELCADE TM (bortezomib) for Injection
Study Locations (20)
California
- Alta Bates Medical Center - Berkeley
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda Cancer Research Institute - Loma Linda
- UCLA School of Medicine - Los Angeles
- Stanford University - Palo Alto
Illinois
- The Rush Cancer Center - Chicago
- University of Chicago Medical Center - Chicago
New York
- Beth Israel Medical Center - New York
- St Lukes-Roosevelt Hospital - New York
Alabama
- University of Alabama - Birmingham
Colorado
- University of Colorado Cancer - Denver
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Georgia
- The Emory Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063713
The ClinicalTrials.gov registry entry for NCT00063713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (48% higher). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which VELCADE TM (bortezomib) for Injection is the first listed.
NCT00063713 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00063713 about?
NCT00063713 is a clinical study titled "VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma". The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
What is the current status of trial NCT00063713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2003-06.
What conditions does trial NCT00063713 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma.
What interventions are being tested in trial NCT00063713?
The interventions under investigation include: VELCADE TM (bortezomib) for Injection (DRUG).
Who is sponsoring clinical trial NCT00063713?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00063713 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RECRUITING · Phase 2
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.